News Agency
Men's Weekly

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

  • Written by Media Outreach
HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological...

Read more: AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth...

Handling Breaking Content Changes Without Frontend Downtime

If you work with software for long enough, you’ll eventually run into a situation where something has to change. Content models have to change; fields have to be renamed; structures will have to be changed and new things added. It... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion